Cited by 42Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase SignalingPI3K/AKT/mTOR signaling in cancer

PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development

Sents, Ward, Meeusen, Bob, Kalev, Petar, Radaelli, Enrico, Sagaert, Xavier, Miermans, Eline, Haesen, Dorien, Lambrecht, Caroline +5 more·2017·Cancer Research

Published version of a preprint

Abstract

Abstract Protein phosphatase 2A (PP2A) complexes counteract many oncogenic kinase pathways. In cancer cells, PP2A function can be compromised by several mechanisms, including sporadic mutations in its scaffolding A and regulatory B subunits or more frequently through overexpression of cellular PP2A inhibitors. Here, we identify a novel genetic mechanism by which PP2A function is recurrently affected in human cancer, involving haploinsufficiency of PPP2R4, a gene encoding the cellular PP2A activator PTPA. Notably, up to 70% of cancer patients showed a heterozygous deletion or missense mutations in PPP2R4. Cancer-associated PTPA mutants exhibited decreased abilities to bind the PP2A-C subunit or activate PP2A and failed to reverse the tumorigenic phenotype induced by PTPA suppression, indicating they function as null alleles. In Ppp2r4 gene-trapped (gt) mice showing residual PTPA expression, total PP2A activity and methylation were reduced, selectively affecting specific PP2A holoenzymes. Both PTPAgt/gt and PTPA+/gt mice showed higher rates of spontaneous tumors, mainly hematologic malignancies and hepatocellular adenomas and carcinomas. These tumors exhibited increased c-Myc phosphorylation and increased Wnt or Hedgehog signaling. We observed a significant reduction in lifespan in PTPA+/gt mice compared with wild-type mice. In addition, chemical-induced skin carcinogenesis was accelerated in PTPA+/gt compared with wild-type mice. Our results provide evidence for PPP2R4 as a haploinsufficient tumor suppressor gene, defining a high-penetrance genetic mechanism for PP2A inhibition in human cancer. Cancer Res; 77(24); 6825–37. ©2017 AACR.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-2911

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Homozygously targeted Ppp2r4 knockout mice (hypomorphic allele) with severely affected PTPA expression (on average only 20% of wild-type levels in most tissues) were born at less than Mendelian ratios, suggestive of embryonic lethality.

    “For instance, homozygously targeted Ppp2r4 KO mice (hypomorphic allele), with severely affected expression of the PP2A activator PTPA (Phosphatase Two A Phosphatase Activator) (on average only 20% of WT levels were left in most tissues), were born at less than Mendelian ratios, suggestive for embryonic lethality [43].”
  • A selective decrease in PP2A-B56γ/ε activity was found in PTPA knockout, while PP2A-B55 activity was unaffected.

    “Interestingly, however, a selective decrease in PP2A-B56γ/ε activity was found, while PP2A-B55 activity was unaffected.”
  • In surviving PTPA knockout mice, overall PP2A-C methylation and activity were significantly reduced (50%).

    “In the surviving PTPA KO mice, overall PP2A-C methylation and activity were significantly reduced (50%).”
  • In Ppp2r4 gt/+ mice, overall survival is decreased.

    “-Embryonic lethality suggested; decreased overall survival in gt/+ mice [43]”
  • Accelerated DMBA/TPA-induced skin papillomas are also observed in heterozygous PTPA knockout mice, in which PP2A-B56γ/ε activity is selectively decreased.

    “Notably, accelerated occurrence of DMBA/TPA-induced skin papillomas was also observed in heterozygous PTPA KO mice, in which activity of PP2A-B56γ/ε (and presumably other PP2A-B56 isoforms) was selectively decreased [43].”

The citation lists haven’t been fetched yet

References 58 · Cited by 42

Authors
Sents, W., Meeusen, B., Kalev, P., Radaelli, E., Sagaert, X., Miermans, E., Haesen, D., Lambrecht, C., Dewerchin, M., Carmeliet, P., Westermarck, J., Sablina, A., & Janssens, V.
Affiliations
  • KU Leuven (BE)
  • VIB-KU Leuven Center for Cancer Biology (BE)
  • Åbo Akademi University (FI)
Venue
Cancer Research
Published
2017-12-14
Volume
77
Issue
24
Pages
6825-6837
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2765105123
Cited by
42
References
58
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 7 · 2018: 7 · 2017: 3
FWCI
2.35
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
protein phosphatase 2A, PTPA, haploinsufficiency, tumor suppressor, PP2A inhibition, spontaneous tumors, hematologic malignancies, hepatocellular carcinoma, c-Myc phosphorylation, Wnt signaling, Hedgehog signaling, skin carcinogenesis, lifespan reduction, null alleles
MeSH terms
Animals, Cell Transformation, Neoplastic, Cells, Cultured, Enzyme Activation, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Phosphoprotein Phosphatases, Genes, Tumor Suppressor, Mice, Protein Phosphatase 2, HEK293 Cells, Haploinsufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review